Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Trombosestichting Nederland | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Theia-study is a prospective, multicenter, single-arm management (cohort) study.
Consecutive patients with clinically suspected acute, recurrent, ipsilateral, proximal deep vein thrombosis (DVT) of the leg, who fulfil all the inclusion criteria and meet none of the exclusion criteria, are eligible for inclusion and will be managed according to the result of a magnetic resonance direct thrombus imaging (MRDTI) of the affected leg. The MRDTI is to be performed and adjudicated within 24 hours of study inclusion. The final treatment decision will be made based on this ruling of the MRDTI. In case of a positive MRDTI signal, patients will be treated with therapeutically dosed anticoagulants or modified in patients with a recurrent DVT on anticoagulant therapy. Patients with a negative MRDTI ruling will be left untreated, or treatment will be remained unadjusted if they are on anticoagulant treatment at inclusion. All patients with negative MRDTI will be subjected to a standardized compression ultrasonography (CUS) within 48 hours after initial presentation. The latter CUS serves as a reference test in case the patient returns with symptoms of ipsilateral recurrence in the future, and will not be used for management decisions at baseline. The study flowchart can be found in Appendix A.
All patients will be followed for three months for the occurrence of acute recurrent venous thrombo-embolism (VTE). In case of suspected recurrent VTE, objective testing including either computed tomography pulmonary angiography (CTPA) for PE or CUS for DVT will be performed. Additionally, in case of a proven ipsilateral recurrent DVT during follow-up, MRDTI will be repeated.
See below.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Phase 4 cohort study | Other | MRDTI |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MRDTI | Other | MRDTI is primary diagnostic test for management of suspected ipsilateral DVT |
|
| Measure | Description | Time Frame |
|---|---|---|
| 3-month incidence of recurrent VTE in patients with negative MRDTI | Primary outcome is subdivided in two main outcomes: 3-month incidence of recurrent VTE in 1) patients with negative MRDTI for both DVT and thrombophlebitis who were not treated with any anticoagulant during follow-up and 2) all patients with negative MRDTI for DVT; these recurrences need to be objectively confirmed by either CT (for acute PE), or CUS with the baseline CUS serving as reference. | 3-month follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| 3-month incidence of recurrent VTE in patients with normal D-dimer test and unlikely clinical probability according to the Wells clinical decision rule for DVT | the 3-month incidence of recurrent VTE in patients with low probability Wells score and a normal D-dimer test at baseline | 3-month follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| The feasibility of MRDTI in day to day clinical practice | The feasibility of MRDTI in day to day clinical practice: percentage of eligible patients that had to be excluded due to logistic reasons such as unavailability of MRDTI within 24 hours of presentation. | First 24 hours after presentation to the emergency ward (post-hoc analysis) |
Inclusion Criteria:
Exclusion Criteria:
Note: *From August 2015 onward, patients with suspected acute, recurrent, ipsilateral DVT on anticoagulant treatment were allowed in the study as they were found to represent a high proportion (30%) of the screened study population.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| F.A. Klok Klok, MD PhD | Department of Thrombosis and Hemostasis, LUMC, Leiden | Principal Investigator |
| M.V. Huisman, Prof | Department of Thrombosis and Hemostasis, LUMC, Leiden | Principal Investigator |
| L.J.M. Kroft, MD PhD | Department of Radiology, LUMC, Leiden | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ottawa Hospital | Ottawa | Canada | ||||
| RAMBAM Healthcare center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24928859 | Result | Tan M, Mol GC, van Rooden CJ, Klok FA, Westerbeek RE, Iglesias Del Sol A, van de Ree MA, de Roos A, Huisman MV. Magnetic resonance direct thrombus imaging differentiates acute recurrent ipsilateral deep vein thrombosis from residual thrombosis. Blood. 2014 Jul 24;124(4):623-7. doi: 10.1182/blood-2014-04-566380. Epub 2014 Jun 13. | |
| 18433464 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020246 | Venous Thrombosis |
| D012008 | Recurrence |
| ID | Term |
|---|---|
| D013927 | Thrombosis |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Inter-observer variability of MRDTI |
The inter-observer variability of MRDTI in daily clinical practice: all MRDTI scans will be review post-hoc by two independent experts to determine the alpha statistic between the readings in clinical practice and that by experts. |
| After the study has been completed, all MRDTI studies will be re-evaluated (post-hoc analysis) |
| a formal cost-effectiveness and cost-utility analysis | A Markov model will be developed to estimate the cost-effectiveness MRDTI versus ultrasonography. The model will follow the patients through the course of disease in a maximum of two three-month cycles, and will include all relevant clinical outcomes and incorporated health states stratified by diagnostic management. Clinical events included in the model are fatal PE, recurrent VTE, major bleeds and clinically relevant non-major. The model includes clinical and cost outcomes, along with incremental cost-effectiveness ratios (ICERs) and net monetary benefits (NMBs). | This model will be based on the primary and secondary endpoints, scored after a follow-up period of 3 months (post-hoc analysis) |
| Haifa |
| Israel |
| AMC | Amsterdam | Netherlands |
| Rijnstate | Arnhem | Netherlands |
| Deventer Ziekenhuis | Deventer | Netherlands |
| LUMC | Leiden | 2333 ZA | Netherlands |
| HAGA | The Hague | Netherlands |
| MCH Westeinde | The Hague | Netherlands |
| Diakonessenhuis Utrecht | Utrecht | 3582 KE | Netherlands |
| UMCU | Utrecht | Netherlands |
| Ostfold Hospital Trust | GrĂ¥lum | Norway |
| Danderyds sjukhus | Stockholm | Sweden |
| Westerbeek RE, Van Rooden CJ, Tan M, Van Gils AP, Kok S, De Bats MJ, De Roos A, Huisman MV. Magnetic resonance direct thrombus imaging of the evolution of acute deep vein thrombosis of the leg. J Thromb Haemost. 2008 Jul;6(7):1087-92. doi: 10.1111/j.1538-7836.2008.02986.x. Epub 2008 Jul 1. |
| 32016390 | Derived | van Dam LF, Dronkers CEA, Gautam G, Eckerbom A, Ghanima W, Gleditsch J, von Heijne A, Hofstee HMA, Hovens MMC, Huisman MV, Kolman S, Mairuhu ATA, Nijkeuter M, van de Ree MA, van Rooden CJ, Westerbeek RE, Westerink J, Westerlund E, Kroft LJM, Klok FA; Theia Study Group. Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. Blood. 2020 Apr 16;135(16):1377-1385. doi: 10.1182/blood.2019004114. |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |